Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis

Abstract Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory to hydroxyurea. Ruxolitinib has been shown to improve symptoms in patients with ET. This post hoc analysis compared the clinical outc...

書誌詳細
出版年:	eJHaem
主要な著者:	Michael R. Grunwald, Ellen K. Ritchie, Elisa Rumi, Albert Assad, J. E. Hamer‐Maansson, Jingbo Yu, Tricia Kalafut, Evan Braunstein, Francesco Passamonti
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2024-08-01
主題:	essential thrombocythaemia hydroxyurea matched‐cohort analysis ruxolitinib
オンライン･アクセス:	https://doi.org/10.1002/jha2.954

類似資料

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS
著者:: Michael Grunwald, 等
出版事項: (2023-08-01)

Leukocytoclastic vasculitis in JAK2-positive essential thrombocythemia: a case of cytokine-driven urticarial rash responsive to ruxolitinib
著者:: Murad Aldarayseh, 等
出版事項: (2025-07-01)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
著者:: Hans Michael Kvasnicka, 等
出版事項: (2018-03-01)

A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide
著者:: Ekrem Yetiskul, 等
出版事項: (2024-02-01)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
著者:: Jumoke Okikiolu, 等
出版事項: (2023-01-01)

Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
著者:: Abhinav Mathur, 等
出版事項: (2022-11-01)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
著者:: Srdan Verstovsek, 等
出版事項: (2023-07-01)

The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis
著者:: Yuxia Pan, 等
出版事項: (2022-12-01)

Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
著者:: Kittitat Chiaranairungrot, 等
出版事項: (2022-12-01)

Hydroxyurea-induced melanonychia
著者:: Michael G. Buontempo, BS, 等
出版事項: (2023-12-01)

Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review
著者:: Jona F. Houthuys, 等
出版事項: (2022-12-01)

Melanoma during Ruxolitinib Treatment for Myelofibrosis
著者:: Lingzhi Zhong, 等
出版事項: (2025-07-01)

Hydroxyurea-induced Tooth Discoloration
著者:: Muhammed Okuyucu, 等
出版事項: (2020-02-01)

In Vitro Hb Production in Β-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
著者:: Mohammad Reza MAHDAVI, 等
出版事項: (2017-06-01)

Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review
著者:: Nobuyasu Hirai, 等
出版事項: (2020-01-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
著者:: Eylem Eliaçık, 等
出版事項: (2015-05-01)

Efficacy of topical ruxolitinib for cutaneous dermatomyositis
著者:: Aviya Lanis, MD, 等
出版事項: (2024-03-01)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
著者:: Jeffrey S. Smith, MD, PhD, 等
出版事項: (2023-08-01)

Letter in response to the case report “Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis”
著者:: Meron Teklu, MD, 等
出版事項: (2023-12-01)

Hydroxyurea treatment inhibits proliferation of Cryptococcus neoformans in mice
著者:: Kaushlendra eTripathi, 等
出版事項: (2012-05-01)

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
著者:: Lewis Carpenter, 等
出版事項: (2022-08-01)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
著者:: Giacomo Coltro, 等
出版事項: (2023-04-01)

Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia
著者:: Ali Ghasemi, 等
出版事項: (2012-10-01)

Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia
著者:: Ali Ghasemi, 等
出版事項: (2015-10-01)

Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
著者:: Khayat André Salim, 等
出版事項: (2004-01-01)

Dermatomyositis-Like Eruption Associated with Hydroxyurea Therapy
著者:: Katarzyna Winkel, 等
出版事項: (2025-06-01)

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
著者:: Sakiyama E, 等
出版事項: (2020-04-01)

Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania
著者:: Manase Kilonzi, 等
出版事項: (2021-11-01)

Hydroxyurea ulcers of unusual location: a case report and review of literature
著者:: Miguel Mansilla-Polo, 等
出版事項: (2023-11-01)

Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea
著者:: I A Lagunju, 等
出版事項: (2013-01-01)

Effect of treatment with hydroxyurea on calcium homeostasis in β-thalassemia-major patients
著者:: Khaled H Hassan
出版事項: (2021-01-01)

Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis
著者:: Shu-yi Guo, 等
出版事項: (2025-12-01)

The study of relationships between β-globin gene mutations in β-thalassaemia patients, in response to hydroxyurea treatment
著者:: S. Zeinali, 等
出版事項: (2008-01-01)

Hydroxyurea usage awareness among patients with sickle‐cell disease in Saudi Arabia
著者:: Mortadah Alsalman, 等
出版事項: (2021-12-01)

Essential Thrombocythemia in a Two-year-old Child, Responsive to Hydroxyurea but Not Aspirin
著者:: Tariq N. Aladily, 等
出版事項: (2017-06-01)

Dermatomyositis-like Eruptions, Hydroxyurea-Associated Squamous Dysplasia, and Nonmelanoma Skin Cancer: A Case Report and Systematic Review
著者:: Giorgia Di Marco, 等
出版事項: (2025-03-01)

Hydroxyurea ameliorates mouse hypoxia through inducing embryonic hemoglobin
著者:: ZHOU Xiaoying, 等
出版事項: (2023-01-01)

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report
著者:: Meltem Aylı, 等
出版事項: (2015-05-01)

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
著者:: Vincenzo Accurso, 等
出版事項: (2019-03-01)

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review
著者:: Xiaohong Liu, 等
出版事項: (2025-08-01)